"While GLP-1s are highly beneficial, there is potential for harm in certain patients." – Dr. Micah Eimer, Northwestern Medicine
Study Overview
A new study from Northwestern Medicine scientists has identified a significant safety signal for patients taking popular GLP-1 drugs. The research found that patients already on at least two classes of antihypertensive medications experienced higher rates of hypotensive events—including dizziness, fainting, and falls—after starting GLP-1 therapy.
Key Findings
The study analyzed health records from more than 42,000 adults. Researchers tracked hypotensive events at 6, 12, and 24 months after patients began treatment with semaglutide, tirzepatide, or liraglutide, and compared these rates to those recorded before treatment began.
Events tracked included:
- Dizziness
- Fainting (syncope)
- Falls
- New diagnoses of low blood pressure
- Systolic blood pressure readings below 90 mm Hg
- New prescriptions for hypotension medications
The highest rates of these adverse events were observed in patients aged 65 and older and those living with diabetes.
Researcher Statement
Study senior author Dr. Micah Eimer, a cardiologist at Northwestern Medicine, emphasized the importance of monitoring. "While GLP-1s are highly beneficial, there is potential for harm in certain patients," he said. He specifically noted the need for careful oversight, particularly for individuals obtaining GLP-1s without direct clinical supervision.
Presentation
The findings are scheduled to be presented on June 13, 2026, at ENDO 2026, the Endocrine Society's annual meeting.